Orgenesis Inc. (ORGS) Income Statement Analysis

See more : REF Holdings Limited (1631.HK) Income Statement Analysis – Financial Results

Complete financial analysis of Orgenesis Inc. (ORGS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Orgenesis Inc., a leading company in the Biotechnology industry within the Healthcare sector.

You may be interested

Orgenesis Inc. (ORGS)

Industry: Biotechnology

Sector: Healthcare

Website: https://www.orgenesis.com

About Orgenesis Inc.

Orgenesis Inc., a biotech company, focusing on cell and gene therapies worldwide. The company develops a Point of Care (POCare) platform that includes a pipeline of licensed POCare therapeutics that are processed and produced in closed automated POCare technology systems across a collaborative POCare network. It focuses on autologous therapies, with processes and systems that are developed for each therapy using a closed and automated processing system approach that is validated for compliant production near the patient at their point of care for treatment of the patient. The company was formerly known as Business Outsourcing Service, Inc. and changed its name to Orgenesis Inc. in August 2011. Orgenesis Inc. was incorporated in 2008 and is based in Germantown, Maryland.

Metric	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008
Revenue	530.00K	36.03M	35.50M	7.65M	33.26M	18.66M	10.09M	6.40M	2.97M	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Cost of Revenue	6.26M	20.44M	28.16M	30.62M	18.12M	10.70M	6.81M	7.66M	3.88M	0.00	0.00	0.00	0.00	0.00	0.00	500.00
Gross Profit	-5.73M	15.59M	7.34M	-22.97M	15.14M	7.96M	3.28M	-1.26M	-906.00K	0.00	0.00	0.00	0.00	0.00	0.00	-500.00
Gross Profit Ratio	-1,080.19%	43.26%	20.68%	-300.13%	45.53%	42.65%	32.53%	-19.70%	-30.46%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Research & Development	11.09M	6.01M	36.64M	83.99M	12.46M	6.46M	2.48M	2.16M	1.07M	1.69M	1.64M	2.31M	0.00	0.00	0.00	0.00
General & Administrative	34.62M	16.16M	15.40M	19.35M	25.25M	16.61M	10.69M	6.45M	4.04M	2.88M	3.82M	2.68M	72.35K	21.17K	25.65K	0.00
Selling & Marketing	464.00K	-566.00K	-687.00K	-380.00K	1.15M	1.21M	599.00K	397.00K	326.00K	144.00K	187.83K	140.94K	0.00	0.00	0.00	0.00
SG&A	34.62M	16.16M	14.71M	18.97M	25.25M	16.61M	10.69M	6.45M	4.04M	2.88M	3.82M	2.68M	72.35K	21.17K	25.65K	3.00K
Other Expenses	0.00	788.00K	-1.33M	474.00K	2.04M	-1.02M	1.63M	2.12M	1.20M	0.00	0.00	0.00	0.00	0.00	0.00	3.00K
Operating Expenses	45.76M	22.95M	50.02M	103.43M	39.74M	22.06M	14.80M	10.23M	6.31M	4.58M	5.46M	4.99M	72.35K	21.17K	25.65K	3.00K
Cost & Expenses	52.01M	43.39M	50.02M	103.43M	57.86M	32.75M	21.60M	17.88M	10.19M	4.58M	5.46M	4.99M	72.35K	21.17K	25.65K	3.50K
Interest Income	0.00	1.82M	943.00K	1.25M	498.00K	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Interest Expense	2.17M	1.82M	1.29M	1.06M	461.00K	2.75M	1.23M	689.00K	696.00K	691.09K	172.51K	0.00	0.00	0.00	0.00	0.00
Depreciation & Amortization	1.56M	1.98M	1.86M	1.44M	3.81M	2.62M	2.60M	2.92M	1.99M	4.55K	3.26K	1.41K	0.00	15.00K	0.00	0.00
EBITDA	-60.72M	-8.30M	-15.72M	-94.21M	-18.91M	-12.39M	-9.85M	-9.04M	-2.64M	-4.80M	-5.36M	-5.00M	-72.35K	-6.17K	-25.65K	-3.50K
EBITDA Ratio	-11,456.23%	-19.15%	-39.00%	-1,244.08%	-62.73%	-65.47%	-100.96%	-135.77%	-175.52%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Income	-53.64M	-7.37M	-42.68M	-95.78M	-24.60M	-14.65M	-11.23M	11.28M	-7.21M	-4.58M	-5.46M	-4.99M	-72.35K	-21.17K	-25.65K	-3.50K
Operating Income Ratio	-10,120.00%	-20.45%	-120.22%	-1,251.71%	-73.98%	-78.53%	-111.31%	176.29%	-242.47%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Total Other Income/Expenses	-10.81M	-1.85M	-1.15M	-1.63M	-47.00K	-2.83M	-3.66M	-1.26M	1.85M	-927.10K	-78.66K	-519.21K	0.00	-15.00K	0.00	0.00
Income Before Tax	-64.44M	-11.96M	-17.95M	-96.74M	-25.48M	-17.77M	-13.68M	-10.74M	-5.36M	-5.50M	-5.54M	-5.00M	-72.35K	-36.17K	-25.65K	-3.50K
Income Before Tax Ratio	-12,159.43%	-33.20%	-50.56%	-1,264.19%	-76.61%	-95.24%	-135.56%	-167.91%	-180.26%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Income Tax Expense	473.00K	209.00K	108.00K	-1.61M	563.00K	1.34M	-1.31M	-1.55M	-900.00K	691.09K	172.51K	9.58K	0.00	0.00	0.00	0.00
Net Income	-55.36M	-12.17M	-18.06M	-95.13M	-26.04M	-18.29M	-12.37M	-9.19M	-4.46M	-5.50M	-5.54M	-5.00M	-72.35K	-36.17K	-25.65K	-3.50K
Net Income Ratio	-10,445.47%	-33.78%	-50.87%	-1,243.17%	-78.30%	-98.05%	-122.58%	-143.72%	-150.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EPS	-1.91	-0.48	-0.74	-4.46	-1.64	-1.37	-1.28	-1.08	-0.96	-1.22	-1.32	-1.11	-0.01	-0.01	0.00	0.00
EPS Diluted	-1.91	-0.48	-0.74	-4.46	-1.64	-1.37	-1.27	-1.08	-0.94	-1.21	-1.32	-1.11	-0.01	-0.01	0.00	0.00
Weighted Avg Shares Out	29.01M	25.10M	24.27M	21.32M	15.91M	13.37M	9.68M	8.52M	4.65M	4.51M	4.20M	4.52M	6.71M	6.71M	6.71M	6.71M
Weighted Avg Shares Out (Dil)	29.01M	25.10M	24.27M	21.32M	15.91M	13.37M	9.71M	8.52M	4.74M	4.56M	4.21M	4.52M	6.71M	6.71M	6.71M	6.71M

Orgenesis leading the charge at an exciting time for cell therapy

August 31, 2021proactiveinvestors.com

Global biotech unlocking the potential of personalized therapies and closed processing systems helpful in manufacturing Maryland-based firm has a Cell and Gene Therapy (CGT) Biotech platform The platform consists of three core elements: POCare Therapeutics, POCare Technologies, and POCare Network...

Orgenesis strikes collaboration agreement with Savicell Diagnostics to advance its cell and gene therapy platform

August 23, 2021proactiveinvestors.com

Orgenesis Inc announced a new collaboration with biotech firm Savicell Diagnostics Ltd to accelerate the development and manufacturing of its cell and gene therapy platform. The wide-ranging agreement sees Orgenesis using Savicell's immunometabolism platform to help advance its own platforms...

Orgenesis Announces Collaboration Agreement with Savicell to License and Deploy its ImmunoBiopsy™ Platform

August 23, 2021globenewswire.com

Goal to accelerate development, QC testing and manufacturing of Orgenesis' cell and gene therapy platform

Orgenesis sees 2Q 2021 revenue jump by 500% year-over-year

August 5, 2021proactiveinvestors.com

Orgenesis Inc said its 2Q 2021 revenues rose from $1.75 million to $10.5 million compared to the same period in 2020. The international biotech company, which is focused on unlocking the full potential of cell and gene therapies (CGTs) in...

Orgenesis Schedules Second Quarter 2021 Business Update Conference Call

August 3, 2021globenewswire.com

GERMANTOWN, Md., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Orgenesis Inc . (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies, today announced that it plans to host a conference...

Orgenesis says Ranpirnase advancing towards multiple indications after FDA consultation and presentation of positive results

July 6, 2021proactiveinvestors.com

Orgenesis Inc (NASDAQ:ORGS) (FRA:45O) has announced multiple milestones in the development of Ranpirnase for multiple indications, including anogenital warts, adenoviral conjunctivitis and even coronavirus (COVID-19). First, Orgenesis has completed its pre-Investigational New Drug (IND) consultation with the US Food and...

Wall Street climbs higher after inflation beats forecasts

June 10, 2021proactiveinvestors.com

12:15pm: S&P 500 goes for a record The Dow was up 108 points, 0.3%, to 34,555 at midday. The Nasdaq added 71 points, 0.5%, to 13,983, and the S&P improved 17 points, 0.4%, to 4,237, which would be a record.

Orgenesis says enrollment is underway for a Phase 2 rotator cuff repair study of its Tissue Genesis Icellator

June 10, 2021proactiveinvestors.com

Orgenesis Inc (NASDAQ:ORGS) (FRA:45O) announced that enrollment has commenced for a clinical trial using the company's Tissue Genesis Icellator in rotator cuff repair surgeries at the Hospital for Special Surgery (HSS) in New York. The Phase 2 trial, supported by...